Among uveal melanomas categorized as class 1, those with high levels of PRAME mRNA were more likely to metastasize than those with low levels of PRAME mRNA, suggesting that patients who have class...
Biofrontera AG (FSE: B8F), the specialist for sun-induced skin cancer, presented data from three pivotal Phase III trials for its lead drug candidate BF-200 ALA at the 14th Annual South Beach...
Researchers at the University of Arizona College of Pharmacy have discovered that a compound found in the natural food additive annatto prevents the formation of cancer cells and skin damage from UV...
Novartis has announced that Tafinlar® (dabrafenib) + Mekinist® (trametinib), the first oral targeted combination therapy to be licensed for advanced melanoma, is now available in the UK...
Women younger than 40 when diagnosed with melanoma reported initiating indoor tanning at an earlier age and more frequent tanning than older women diagnosed with the potentially fatal skin cancer...
A first-of-its-kind (anti-PD-1) immunotherapy has been approved by the U.S. Food & Drug Administration as first-line treatment for metastatic melanoma, allowing greater access to this therapy for...
A sunscreen that encapsulates the benefits of current commercial products within nanotechnology offers protection without harm as it does not enter the bloodstream.
The combination of cobimetinib and Zelboraf® (vemurafenib) has been shown to extend the lives of previously untreated patients with advanced skin cancer to nearly two years (22.
US regulators have approved a drug combination - vemurafenib (Zelboraf) and cobimetinib (Cotellic) - for advanced melanoma that shows great promise in extending patients' lives.